QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

• Conditions: Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
• Interventions: Drug: Iparomlimab and Tuvonralimab (QL1706)Injection; Drug: Paclitaxel; Drug: Cisplatin

• Registration Number: NCT06852456
• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Brief Summary

This is a randomized, double-blind, placebo-controlled Phase II/III clinical trial to evaluate the perioperative treatment with QL1706 in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal squamous cell carcinoma. The primary objective of the Phase II is to evaluate the pathological complete response rate of QL1706 perioperative treatment in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal squamous cell carcinoma; the primary objective of the Phase III is to compare event-free survival of QL1706 perioperative treatment in combination with neoadjuvant chemotherapy versus placebo in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal squamous cell carcinoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-20
• Study First Submitted QC: 2025-02-24
• Last Update Submitted: 2025-02-24
• Study First Posted: 2025-02-28
• Last Update Posted: 2025-02-28
• Study Start: 2025-03
• Primary Completion: 2030-12
• Study Completion: 2034-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.
• Patients with thoracic esophageal squamous cell carcinoma diagnosed by pathologic histology or cytology and cT1-2N1-3M0 or cT3-4aN0-3M0 according to AJCC/UICC 8th edition.
• Expected to undergo surgery after completion of neoadjuvant therapy and expected to achieve R0 resection.
• Have not receiv any anti-tumor therapy for esophageal cancer.
• Have adequate organ function.

Exclusion Criteria

• Significant tumor invasion into organs adjacent to the esophageal lesion;
• a history of gastrointestinal bleeding or those with a high bleeding tendency;
• The presence of supraclavicular lymph node metastases;
• the presence of uncontrollable third interstitial fluid;
• poor nutritional status.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
QL1706 injection combined with chemotherapy	Iparomlimab and Tuvonralimab (QL1706)Injection	-
QL1706 injection combined with chemotherapy	Paclitaxel	-
QL1706 injection combined with chemotherapy	Cisplatin	-

Primary Outcome Measures

Name	Time	Method
Pathologic complete response rate (pCR) as assessed by the investigator; (Phase II stage)	30 days after operation	pCR rate was defined as the percentage of subjects with no tumor residue in the primary tumor and regional lymph nodes.
Event-Free Survival (EFS) as assessed by BIRC; (Phase III stage)	up to 5 years	EFS is defined as the time from randomization (for Phase II: from first dose) to the occurrence of an imaging disease progression/recurrence or death event from any cause, whichever occurs first.